Channels - Real-World Persistence with Anti-VEGF Therapy in Neovascular Age-related Macular Degeneration :: FRELIP Discovery

Similar Items: Real-World Persistence with Anti-VEGF Therapy in Neovascular Age-related Macular Degeneration

Quick Look
Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval
Quick Look
Two-Year Real-World Outcomes of Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
Quick Look
Influence of Anti-VEGF Injections on Longitudinal Changes in Vascular Metrics Measured by OCTA in Age Related Macular Degeneration: A Retrospective Real-World Study
Quick Look
Prospective Real-World Outcomes After Switching to Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration with High Treatment Burden
Quick Look
Real-Life 1-Year Results and Predictors of Visual Outcome with Intravitreal Faricimab for Treatment of Exudative Neovascular Age-Related Macular Degeneration
Quick Look
Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US
Quick Look
Safety of GBL1204—An Ophthalmic Bevacizumab in Prefilled Syringe for Neovascular Age-Related Macular Degeneration: A Phase I Study
Quick Look
NICE-Informed Quality Improvement for Neovascular Age-Related Macular Degeneration: A Single-Centre Two-Cycle Audit of the Two-week Referral-to-Injection Standard
Quick Look
Summary of Research: Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials
Quick Look
Letter to the Editor Regarding “Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials”
Quick Look
A Response to: Letter to the Editor Regarding “Aflibercept 8 mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials”
Quick Look
Clinical Outcomes of Neovascular Glaucoma in Patients with Prior and Non-Prior Intravitreal Anti-VEGF Treatment: A Retrospective Cohort Study
Quick Look
Identification of OCTA Biomarkers and Cutoff Values Associated with Disease Severity in Dry Age-Related Macular Degeneration
Quick Look
Systemic and ocular complications related to intravitreal administration of anti-VEGF agents
Quick Look
The Evolving Role of Anti-VEGF Therapy in Proliferative Diabetic Retinopathy: Evidence, Challenges, and Future Directions
Quick Look
Retrograde Maculopathy or Microcystic Macular Degeneration in Patients With Optic Neuritis due to Neuromyelitis Optica
Quick Look
Macular Neovascular Membrane as a Late Complication of Acute Posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE) Managed With Intravitreal Aflibercept
Quick Look
Efficacy and Safety Outcomes of Fluocinolone Acetonide Intravitreal Implant in Refractory Diabetic Macular Edema: A Real-World Study
Quick Look
Functional Real-World Outcomes of Aflibercept 8 mg Versus Faricimab After Loading Phase in Diabetic Macular Edema
Quick Look
Real-World Outcomes After Switching to Faricimab in Patients with Chronic Diabetic Macular Edema at a Tertiary Eye Center in Singapore
Quick Look
Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report
Quick Look
Aflibercept 24-Month Outcomes in Diabetic Macular Edema With and Without Prior Macular Laser Therapy: Data from the Fight Retinal Blindness! Registry
Quick Look
Fluorescein Angiography Leakage Patterns in Pachychoroid Neovasculopathy: Neovascularization or Central Serous Chorioretinopathy?
Quick Look
Prevalence and Visual Acuity Characteristics of Patients with Macular Telangiectasia